OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
SHANGHAI, Dec. 5, 2025 /PRNewswire/ -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a $100...
Model ML raises $75M In One of The Largest FinTech Series A Rounds In History to Transform Financial Services with AI Workflow Automation
NEW YORK, Nov. 24, 2025 /PRNewswire/ -- Model ML, the leading global AI workflow automation platform for financial services, today announced a $75 million Series A financing led by FT Partners, the global leader in FinTech investment banking. The...
Mine Vision Systems Announces $12.5 Million Series A to Accelerate Underground Mining Decision Platform
PITTSBURGH, Nov. 5, 2025 /PRNewswire/ -- Mine Vision Systems (MVS), the leader in vision-driven mapping and analytics for underground mining, today announced a $12.5 million Series A financing led by Rockwell Venture Capital with a significant...
FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA
CARDIFF-BY-THE-SEA, Calif., April 22, 2025 /PRNewswire/ -- Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of $40 million in Series A financing. The round includes $20 million...
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing led by Frazier Life Sciences with significant...
Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases
BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its...
Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage...
Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage...